Therapeutic formulations and methods

Patent metadata

Field	Value
Publication number	US-9757354-B2
Application number	US-201615177150-A
Country	US
Kind code	B2
Filing date	Jun 8, 2016
Priority date	Jun 8, 2015
Publication date	Sep 12, 2017
Grant date	Sep 12, 2017

Abstract

The invention provides compositions and methods for treating cyanide poisoning.

First claim

What is claimed is:

1. A pharmaceutical composition comprising, sulfanegen lysine, lysine hydrochloride, and water.

2. The composition of claim 1 wherein the molar ratio of sulfanegenic acid:lysine is about 1:2.

3. The composition of claim 1 wherein the molar ratio of sulfanegenic acid:lysine:lysine hydrochloride is about 1:2:0.4.

4. The composition of claim 1 , which is formulated for intramuscular administration.

5. The composition of claim 1 , which is formulated for intravenous administration.

6. The composition of claim 1 having a pH of greater than about 4.

7. The composition of claim 1 having a pH of less than about 5.

8. The composition of claim 1 , which is formulated for intraosseous administration.

9. A pharmaceutical composition prepared by combining sulfanegen lysine, lysine hydrochloride, and water.

10. A pharmaceutical composition prepared by combining sulfanegenic acid and a solution of lysine in water.

11. A pharmaceutical composition prepared by combining sulfanegenic acid and a solution prepared by combining water, lysine and lysine hydrochloride.

12. A pharmaceutical composition comprising sulfanegenic acid solid, lysine solid, and lysine hydrochloride solid.

13. A pharmaceutical composition prepared by combining sulfanegenic acid solid, lysine solid, and lysine hydrochloride solid.

14. A method comprising combining a) a solution prepared by combining water, lysine and lysine hydrochloride and b) sulfanegenic acid to provide a resulting solution.

15. The method of claim 14 further comprising administering the resulting solution to an animal.

16. The method of claim 15 wherein the resulting solution is administered to the animal at least 1 hour after combining.

17. The method of claim 15 wherein the resulting solution is administered to the animal at least 15 hours after combining.

18. A method comprising combining a) water and b) sulfanegenic acid solid, lysine solid, and lysine hydrochloride solid to provide a resulting solution.

19. A kit comprising a) a solution prepared by combining water, lysine and lysine hydrochloride; b) sulfanegenic acid solid; and instructions for combining the solution and the solid to provide a composition suitable for treating cyanide poisoning.

20. A kit comprising a) sulfanegenic acid solid, lysine solid, and lysine hydrochloride solid; and instructions for combining the sulfanegenic acid solid, lysine solid, and lysine hydrochloride solid with water to provide a composition suitable for treating cyanide poisoning.

21. A nanoparticle comprising sulfanegen lysine and lysine hydrochloride.

22. A nanoparticle suspension comprising a plurality of nanoparticles as described in claim 21 .

23. A pharmaceutical composition comprising a plurality of nanoparticles as described in claim 21 and a pharmaceutically acceptable carrier.

Assignees

• Univ Minnesota

Inventors

• Patterson Steven Earl
• Nagasawa Herbert Tsukasa
• Vince Robert
• Monteil Alexandre

Classifications

• A61K9/16

  Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)} · CPC title

• A61K31/385 Primary

  having two or more sulfur atoms in the same ring · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K31/198

  Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) · CPC title